MedTrace Logo

Potential Drug Interactions With Bisoprolol in Egyptian Patients With ACS

NCT05536284 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2023-06-07

No results posted yet for this study

Summary

Acute coronary syndrome (ACS) is any group of clinical symptoms compatible with acute myocardial ischemia and includes unstable angina (UA), non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). (1). In Egypt, the overall prevalence of coronary heart disease (CHD) is 8.3 % (2). In addition, CHD in Egypt is the principal cause of death, responsible for 21.73% of total mortality (2).

Beta-blockers have shown to reduce the short-term risk of a reinfarction and the long-term risk of all-cause mortality and cardiovascular mortality (3). Beta blockers are used within 24 hours of ACS and given as long-term therapy after discharge (4). The Most frequently used drug in Egypt is bisoprolol. In patients with myocardial infarction undergoing primary percutaneous coronary intervention, early intravenous betablocker before reperfusion reduced infarct size and increased left ventricular ejection fraction (4).drug interactions are common in ACS patients due to polypharmacy and comorbidities.(5) there are limited studies investigating drug interactions with bisoprolol in acute coronary syndrome patients. The proposed research in this application will investigate potential drug interactions with bisoprolol in patients with acute coronary syndrome.

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Bisoprolol Fumarate Tablets

Antihypertensive drug used for acute coronary syndrome patients

Sponsors & Collaborators

  • Alexandria University

    collaborator OTHER

  • Damanhour University

    lead OTHER

Principal Investigators

  • Amira B Kassem, PHD · Lecturer of Clinical Pharmacy, Damanhour University.

  • sherouk okda, bachelor · Clinical Pharmacy Specialist, Damanhour University.

  • Noha ahmed, PHD · Lecturer of Clinical Pharmacy, Damanhour University.

  • ahmad salahaldin, PHD · Lecturer of biochemisrty, Damanhour University.

  • ahmad alamrawy, PHD · cardiologist , alexandria university

  • sohila alonsy, PHD · Lecturer of Analytical chemistry, Damanhour University.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-05-20
Completion
2022-08-16

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05536284 on ClinicalTrials.gov